The COO of Stemline Therapeutics Inc (NASDAQ: STML) is Selling Shares

By Carrie Williams

Yesterday, the COO of Stemline Therapeutics Inc (NASDAQ: STML), Kenneth Hoberman, sold shares of STML for $192.2K.

In addition to Kenneth Hoberman, 3 other STML executives reported Sell trades in the last month. Following Kenneth Hoberman’s last STML Sell transaction on February 16, 2018, the stock climbed by 1.2%.

The company has a one-year high of $18 and a one-year low of $7.05. Currently, Stemline Therapeutics Inc has an average volume of 201.4K.

The insider sentiment on Stemline Therapeutics Inc has been negative according to 18 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. It develops a discovery platform called StemScreen, which identifies novel compounds that target and kill cancer stem cells.